Business · Companies · 2 hrs ago
Sun Pharma reports strong September-quarter growth as Organon deal advances
Sun Pharmaceutical reported double-digit revenue growth in the quarter ending September 2026, supported by business in India, emerging markets and specialty medicines.
One-off acquisition and litigation costs reduced profitability, despite the rise in revenue.
The company is looking to specialty medicines, new launches and research projects to support growth and offset weakness in its US generics business.
Sun's share of India's domestic market rose to 8.6%, up from 8.3% a year earlier.
The proposed Organon acquisition could expand Sun's global reach and strengthen its specialty and biosimilar businesses.
The deal is expected to close by the fourth quarter of FY27, if it receives the required approvals.
Sun Pharmaceutical reported strong double-digit revenue growth in the September 2026 quarter, supported by India, emerging markets and specialty medicines.
One-off acquisition-related and litigation settlement costs weighed on profitability.
The company said its medium-term growth will be driven by specialty medicines, new launches, clinical pipeline progress and market-share gains in India.
Sun’s domestic market share rose to 8.6% from 8.3% a year earlier.
The proposed Organon acquisition is expected to be completed by the fourth quarter of FY27, subject to approvals.
- Who
- Sun Pharmaceutical.
- What
- It reported strong double-digit revenue growth in the September quarter. One-off acquisition-related and litigation settlement costs weighed on profitability.
- When
- The September 2026 quarter.
- Where
- India, emerging markets and the US are mentioned; the company’s domestic market share refers to India.
- Why
- Growth was supported by performance in India, emerging markets and specialty medicines.
This story does not have two clearly opposing sides.
Sun reported strong double-digit revenue growth, while acquisition-related and litigation settlement costs weighed on profitability.
Sun expects the proposed Organon acquisition to be completed, subject to approvals.
- Domestic market share
- 8.6%, up from 8.3% a year earlier
- R&D spending
- 4.8% of sales, compared with 5.4% in the year-ago quarter
- Organon acquisition
- Expected completion by the fourth quarter of FY27, subject to approvals
- Innovative medicines portfolio
- More than one-fifth of Sun’s overall sales
- Target price
- ₹2,300, according to Choice Equity Broking